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Mulibrey Nanism (MUL) is an
autosomal recessively inherited
condition with growth retardation
affecting several tissues of mesodermal
origin.
MUL belongs to the diseases of the
Finnish disease heritage, that is a
number of disorders that occur more
frequently in Finland than elsewhere.
The molecular pathogenesis of MUL is
not known.
In this study a positional cloning
strategy was used to identify the
causative gene for MUL. Initially the
MUL locus was assigned to chromosome
17q by linkage analysis. The assignment
of MUL was further refined to an 800 kb
region by linkage disequilibrium and
haplotype analysis.
A positional candidate gene strategy
was employed since several genes,
cDNA clones, and ESTs were localised
to the MUL region.
The open reading frame of a cDNA
clone, KIAA0898, was analysed by
sequencing overlapping RT-PCR
amplified fragments in four MUL
patients representing five different
haplotypes. Four independent MUL
associated mutations were identified. All
the mutations disrupt the reading frame
predicting a truncated protein, thus
providing strong evidence for
KIAA0898 being the MUL gene.
MUL was identified to be a novel
member of the RING-B-Box-Coiled-
Coil (RBCC) family as the amino acid
sequence has a RING finger, one B-box
motive, and a coiled-coil domain.
Furthermore, MUL was shown to be
ubiquitously expressed corresponding
well with the pleiotropic and
developmental nature of the disorder.
The exact function of the MUL
protein is presently unknown, but
existing members of the RBCC family
play a role in regulation of development
and oncogenesis, both of which are
disrupted in the MUL phenotype. The
identification of the MUL gene is the
first step towards the resolution of the





The Human Genome Project
The Human Genome Project (HGP),
initiated in the mid 1980´s, is an
international undertaking to co-ordinate
the efforts needed for the sequencing of
the human nuclear genome.
To achieve the whole sequence of the
genome one needs high resolution
genetic and physical maps. Much of this
work has already been accomplished.
The integrated genetic maps (e.g.
Weissenbach et al. 1992, Gyapay et al.
1994, Murray et al. 1994, Dib et al.
1996) have on the average a marker
density of one per 0.7 cM (Murray et al.
1994). Furthermore, several
chromosomes and chromosomal regions
are covered by physical maps
(Chumakov et al. 1992, Foote et al.
1992, Cohen et al. 1993, Chumakov et
al. 1995).
The major contributors in the ultimate
effort of sequencing are the Department
of Energy (DOE), Joint Genome
Institute, USA; Baylor College of
Medicine, Human Genome Sequencing
Center, USA; The Sanger Centre, UK;
Washington University, USA; and the
Whitehead Institute for Biomedical
Research/MIT Center for Genome
Research, USA.
By February 2000 already 64% of the
human genomic sequence was available
via internet. About 17% of the genome is
available as finished, high quality
sequence, whereas the remaining 47% is
available as “draft sequence” meaning
that the sequence is of lower accuracy
than the finished sequence and includes
some gaps.
A draft sequence of the entire
genomic sequence is estimated to be
available by summer 2000, and a
complete, high quality human genomic
sequence is estimated to be available by
2003 (http://www.ornl.gov/hgmis/
project/progress.html).
A A major milestone within the HGP
project was recently achieved as the first
sequence of an entire human
chromosome was completed decoding
the sequence of chromosome 22
(Dunham et al. 1999).
Expressed sequence tags
During the last few years the HGP has
put emphasis on the identification of
expressed sequence tags (ESTs). ESTs
represent coding regions of the genome
and they are generated by sequencing
short stretches of cDNA clones.
The major contributors in large-scale
sequencing of cDNA clones are the
Institute of Genomic Research (TIGR)
and Merck Pharmaceuticals.
It has been estimated that only about
20% of human genes are expressed in
such a restricted pattern or level that
they are not likely to be found by
analysing cDNA (Strachan and Read
1996).
By the end of 1999 altogether 1.1
million EST sequences have been
produced from approximately 53,000
human genes. ESTs have provided a
powerful tool for the identification of the
disease genes, as 91% (December, 1997;
http://www.ncbi.nlm.nih.gov/) of
positionally cloned genes mutated in
human diseases are represented by their
exact matches with one or more ESTs in
the EST division of GenBank (dbEST).
Consequences of HGP
Both great expectations and criticism
have been raised due to the actions
within the HGP. As the structure of
every human gene will be revealed,
individuals at risk of a hereditary
disorder can be tested prenatally and
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presymptomatically. The function and
regulation of individual genes can be
determined improving our knowledge on
biological processes. Inevitably, gene
therapy approaches will be increasingly
applied. On the other hand, commercial
exploitation of sequence data, e.g.
patenting human genes has been
objected by the public at large. The
detection of disease associated mutations
raises concern among citizens; will
individuals be discriminated based on
their genes by insurance companies or
employers? These concerns have to be
addressed e.g. by public debate and
proper legislation.
Availability of data
The HGP has developed capabilities for
collecting, storing, distributing, and
analysing all the data produced. A free
access to the data and facilities
developed within the HGP is provided
via internet for the whole scientific
community. This has greatly promoted
the work of academic research groups in
the field of genetics throughout the
world. Vice versa, academic research
groups have also contributed by
submitting their own data to public
databases. Both have also happened in
the positional cloning project of
Mulibrey Nanism gene (MUL) described
in this thesis. Free availability of genetic
and sequence data should be
acknowledged by everyone working in
the field of genetics.
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3. REVIEW OF THE
LITERATURE
3.1. Finnish disease heritage
Basic concept
The concept of Finnish disease heritage
refers to rare, monogenic disorders
occurring more frequently in Finland
than elsewhere (Norio et al. 1973).
Presently, the Finnish disease heritage
includes some 35 disorders (reviewed by
Peltonen et al. 1999). Most of these
disorders are autosomal recessive (Norio
1981). However, the Finnish
amyloidosis type V (Meretoja 1973) and
tibial muscular dystrophy (Udd et al.
1992) represent an autosomal dominant
pattern of inheritance, and two eye
disorders, choroideremia (Shapira &
Sitney 1943) and retinoschisis (Gieser &
Falls 1961), are X-linked.
As a consequence of the same
phenomena that has given raise to the
Finnish disease heritage many hereditary
disorders prevalent in other European
populations, e.g. cystic fibrosis (Lowe et
al. 1949) and Tay-Sachs disease
(Petersen et al. 1983), are exceptionally
rare or absent in the Finnish population
(Norio et al. 1973, Norio 1981, Kere et
al. 1994).
Finnish population history
The unique genome of the Finns has
evolved as a consequence of the Finnish
population history (Norio et al. 1973, de
la Chapelle 1993, Sajantila et al. 1996,
de la Chapelle & Wright 1998, Peltonen
1999, Peltonen et al. 1999, Varilo 1999),
which is characterised by isolation,
several population bottlenecks, and a
restricted number of founders.
Finland was populated soon after the
glacial period, some 10,000 years ago by
settlers of unknown origin. For about
8,000 years Finland remained sparsely
populated. During the first centuries
A.D. a new wave of settlers originating
from western European populations
(Sajantila et al. 1995) immigrated to the
southern and western coastal parts of
Finland (early-settlement areas; Fig. 1).
The Finnish population remained
isolated, partly due to geographical
reasons. Finland is surrounded in the
south and west by the Baltic Sea. In
addition, Finland is located between two
countries, Sweden and Russia, which
have had a distinct culture and religion.
Particularly, the Finns were isolated due
to their language, as Finnish is not
related to Swedish or Russian.
During the following centuries, wars,
diseases and periods of famine inhibited
the growth of the population producing
population bottlenecks. The backlands of
Finland (late-settlement areas; Fig. 1)
were inhabited by people originating
from South Savo during the 16th century
as more land was needed to feed the
increasing population. Moreover, the
Swedish Crown favoured internal
migration by lightening taxation to
occupy the empty backlands close to
Russia.
The small number of settlers
introduced an additional internal
population bottleneck. The new
settlements were distantly located from
each other and separated by forests and
lakes forming sub-isolates within
Finland. The random set of alleles
introduced by the founders established
the gene pool of the sub-isolate; a
phenomenon called the founder effect.
The random alleles introduced by the
founders were enriched due to
consanguineous marriages.
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Meaning of birthplaces
Before the World War II, the majority of
Finns got their living from agriculture
and inhabited the same geographical
region as their ancestors. Consequently,
the birthplaces of the grandparents of
presently living patients represent the
founder region. The Finnish settlement
history and the birthplaces of the
grandparents of presently living patients
can be utilised for a rough estimation of
the age of the mutation (de la Chapelle
& Wright 1998). If the birthplaces are
exclusively scattered in the late-
settlement region it can be hypothesised
that the expansion of the mutation
started after the 16th century, whereas if
the birthplaces are detected also in the
early-settlement region, the expansion of
the mutation most likely has initiated
before the 16th century (de la Chapelle &
Wright 1998; Fig. 1).
An excellent possibility to study genetics
The Finnish disease heritage provides an
excellent possibility to study human
genetics. The high quality of the Finnish
health care system enables the clinical
investigation and diagnosis of rare
hereditary disorders. Population records
established in the 17th century provide
reliable information on births, deaths and
marriages for genealogical studies.
Furthermore, the Finns have a positive
attitude towards medical research. Not
surprisingly, the molecular genetics of
the diseases of the Finnish disease
heritage have been studied extensively.
Until now the gene locus is assigned for
33 disorders, and the underlying gene
has been identified in 22 disorders
(Table 1).
Fig. 1
Map of Finland presenting the early-settlement
and late-settlement regions as well as the region
of South Savo. The black squares represent the
birthplaces of the grandparents of the parents of
the MUL patients. The size of the square refers
to the number of the grandparents. MUL is
clustered in the Savo and North Carelia regions.
(Adapted from Lipsanen-Nyman 1986 and de la
Chapelle 1993.)
Table 1. The diseases of the Finnish disease heritage.
DISEASE, ABBREVIATION LOCUS DEFECTIVE GENE/PROTEIN REFERENCE
The identified genes
Aspartylglucosaminuria, AGU 4q AGA, aspartylglucosaminidase Ikonen et al. 1991
Autoimmune Polyendocrinopathy- 21q AIRE, a novel gene featuring two zinc-finger domains The Finnish-German APECED Consortium
Candidiasis-Ectodermal Dystrophy, APECED 1997, Nagamine et al. 1997
Choroideremia, CHM Xq RAB geranyl-geranyl transferase Cremers et al. 1990
Congenital Chloride Diarrhoea, CLD 7q DRA, down-regulated in adenoma Höglund et al. 1996
Congenital Nephrosis, Finnish type; CNF 19q NPHS1, a novel gene encoding a glomerular protein Kestilä et al. 1998
Cornea plana congenita, CNA2 12q KTN, keratocan, a leucine-rich proteoglycan Pellegata et al. 2000
Diastrophic Dysplasia, DTD 5q DTDST, diastrophic dysplasia sulphate transporter Hästbacka et al. 1994
Familial Amyloidosis, Finnish type; FAF 9q GSN, gelsolin Levy et al. 1990, Maury et al. 1990
Gonadal dysgenesis, FSH-RO 2p FSHR, follicle stimulating hormone receptor Aittomäki et al. 1995
Gyrate Atrophy of Choroid and Retina, HOGA 10q OAT, ornithine delta-aminotransferase Mitchell et al. 1988
Hereditary Fructose Intolerance, HFI 9q ALDOB, aldolase B Cross et al. 1988
Infantile Neuronal Ceroid Lipofuscinosis, INC L 1p PPT, palmitoyl protein transferase Vesa et al. 1995
Lysinuric Protein Intolerance, LPI 14q SLC7A7, a novel gene encoding a putative permease-related protein Borsani et al. 1999, Torrents et al. 1999
Mulibrey Nanism, MUL 17q MUL, a novel gene encoding a RBCC protein III
Nonketotic hyperglycinemia, NKH 9p P protein of glycine cleavage system Kure et al. 1992
Polycystic lipomembranous osteodysplasia 19q TYROBP , TYRO protein tyrosine kinase binding protein Paloneva et al. 2000
with sclerosing leukoencephalopathy, PLOSL
Progressive epilepsy with mental retardation, EPMR 8p CLN8, a novel transmembrane protein Ranta et al. 1999
Progressive myoclonus epilepsy, PME 21q CSTB, cystatin B, a cysteine protease inhibitor Pennacchio et al. 1996
Retinoschisis, RS Xp XLRS1, a novel gene encoding a putative cell adhesion protein Sauer et al. 1997
Salla disease, SD 6q SLC17A5, also known as AST, encoding a sialin Verheijen et al. 1999
Selective intestinal malabsorption of vitamin B12, MGA1 10p CUBN, cubilin, a gene encoding intrinsic factor-vitamin B12 receptor Aminoff et al. 1999
Variant late-infantile neuronal ceroid lipofuscinosis, vINCL 13q CLN5, a novel gene encoding a putative transmembrane protein Savukoski et al. 1998
The mapped genes
Cartilage-hair hypoplasia, CHH 9p Sulisalo et al. 1993
Cohen syndrome, COH1 8q Tahvanainen et al. 1994
Congenital lactase deficiency, CLD 2q Järvelä et al. 1998
Growth retardation with acidosis 2q Visapää et al. 1998
Hydrolethalus syndrome 11q Visapää et al. 1999
Infantile-onset spinocerebellar ataxia, IOSCA 10q Nikali et al. 1995
Lethal congenital contracture syndrome, LCCS 9q Mäkelä-Bengs et al. 1998
Meckel syndrome, MKS 17q Paavola et al. 1995
Muscle-eye-brain disese, MEB 1p Cormand et al. 1999
Tibial muscular dystrophy, TMD 2q Haravuori et al. 1998
Usher syndrome, type III; USH3 3q Sankila et al. 1995
The unmapped loci
Progressive encephalopathy with edema, Salonen et al. 1991
Progressive encephalopathy with edema,
RAPADILINO Kääriäinen et al. 1989
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3.2. Mulibrey Nanism
Mulibrey Nanism (MUL; MUscle-LIver-
BRain-EYe Nanism; MIM No. 253250)
was first described in Finland in the
early 1970´s (Perheentupa et al. 1970
and 1973). It is a typical disorder of the
Finnish disease heritage; the majority of
the reported MUL patients are Finnish,
and the pattern of inheritance is
autosomal recessive.
MUL affects several tissues of
mesodermal origin (Perheentupa et al.
1973) and is evidently caused by a
pleiotropic gene (Perheentupa et al.
1973, Lipsanen-Nyman 1986, Lapunzina
et al. 1995). The molecular pathogenesis
of MUL is not known.
World-wide, some 75 MUL patients
have been described, the majority from
Finland, where the incidence of MUL is
estimated to be 1:40,000 (Lipsanen-
Nyman 1986). In Finland the disease is
clustered in the Savo and North Carelia
regions (Fig. 1) representing early and
late settled areas (de la Chapelle 1993).
Sporadic patients have been reported e.g.
from Egypt (Thoren 1973), Canada
(Cumming et al. 1976), USA (Voorhess
et al. 1976), Spain, and Argentina
(Lapunzina et al. 1995).
Clinical characteristics of MUL
MUL is characterised by growth failure
of prenatal onset. The final height of
MUL patients is on the average 33 cm
below population means. MUL patients
have typical dysmorphic features
including triangular face, broad
forehead, low nasal ridge, and
telecanthus (Perheentupa et al. 1973,
Myllärniemi et al. 1978; Fig. 2).
Fig. 2
A 4 year old Mulibrey Nanism patient. Notice
the overall slenderness of the body. The
borders of the enlarged liver are indicated with
a marker. Also, the characteristic dysmorphic
features, triangular face, prominent forehead,
and low nasal bridge are detected.
REVIEW OF THE LITERATURE
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MUL is also characterised by
yellowish dots in the ocular fundi, J-
shaped sella turcica, enlarged brain
ventricles, prominent jugular veins,
small voice, and muscle hypotonia
(Perheentupa et al. 1973, Lipsanen-
Nyman 1986, Lapunzina et al. 1995).
Hypoplasia of various endocrine glands
causing hormonal deficiencies is
common e.g. growth hormone deficiency,
hypocortisolism, hypothyroidism, and
hypogonadism with infertility have been
reported (Lenko et al. 1982, Lipsanen-
Nyman 1986, Haraldsson et al. 1993).
No signs of intellectual incapacity have
been observed in MUL (Lipsanen-
Nyman 1986). The clinical
characteristics of MUL are summarised
in Table 2.
Table 2. Summary of the findings in Mulibrey Nanism patients (adapted from Lapunzina et al. 1995).
In more than 66% of the patients In at least 25% of the patients In less than 25% of the patients
short stature cutaneous naevi flammei cardiomegaly
growth failure dental malocclusion cortical thickening of long bones
triangular face missing/small sinuses hypodontia of 2nd premolar
J-shaped sella turcica prenatal growth failure strabismus
depressed nasal ridge pulmonary infections large cerebral ventricles
broad nose choroidal hypoplasia ovarian tumour
yellowish dots in ocular fundi ascites/edema corneal dystrophia
prominent jugular veins fibrous dysplasia of tibia high set hyoid bone
hepatomegaly simian crease
small voice eosinophilia
frontal bossing edema of vocal cords
pericardial constriction coloboma of iris
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MUL and tumours
Interestingly, the risk for developing
unclassified ovarian tumours and Wilms´
tumours (WT) is increased in MUL
(Lipsanen-Nyman 1986). Two MUL
patients with WT (Similä et al. 1980,
Seemanová & Bartch 1999) and two
siblings of MUL patients presenting
some signs of MUL and suffering from
WT (Lipsanen-Nyman 1986) have been
reported. WT is one of the most common
solid tumours of childhood. It occurs
usually sporadically in 1 in 10,000
children and accounts for 8% of
childhood cancers (Breslow & Beckwith
1982).
WT is associated with several genetic
disorders e.g. the Beckwith-Wiedeman
syndrome (Koufos et al. 1989),
neurofibromatosis type-1 (Stay &
Vawter 1977), the hereditary
hyperparathyroid-jaw tumour syndrome
(Szabo et al. 1995), the Simpson-Golabi-
Behmel syndrome (Pilia et al. 1996), Li-
Fraumeni syndrome (Hartley et al.
1993), the breast-ovarian cancer
syndrome (Narod 1994), Bloom
syndrome (Cairney et al. 1987), and the
Perlman syndrome (Neri et al. 1984).
MUL and Silver-Russel syndrome
The phenotype of MUL overlaps to
some extent with the phenotype of
Silver-Russell syndrome (SRS; MIM
No. 180860) often creating difficulties in
the differential diagnosis of these
disorders. The main characteristics of
SRS are intrauterine growth retardation,
asymmetry of the limbs, craniofacial
disproportion, and triangular faces.
SRS is a genetically heterogeneous
disorder. Both sporadic (Tanner et al.
1975) and familial (Fuleihan et al. 1971,
Duncan et al. 1990) SRS cases have
been reported. Approximately 10% of
the SRS cases are associated with
maternal uniparental disomy of
chromosome 7 (Joyce et al. 1999).
Recently, a maternally derived de novo
duplication of 7p11.2-13 was identified
in a SRS patient suggesting that
overexpression of an imprinted gene in
this region is responsible for SRS (Monk
et al. 2000).
Additionally, two SRS patients with
an identical translocation at 17q25 have
been reported (Ramirez-Duenas et al.
1992, Midro et al. 1993) suggesting that
a mutation in a gene located in 17q25 is
also responsible for SRS. Association of
SRS with abnormalities of chromosomes
8, 15 and 18 have also been reported
(Chauvel et al. 1975, Scinzel et al. 1994,
Rogan et al. 1996).
Furthermore, X-linked dominant
inheritance has been suggested as no
male-to-male transmission has been
documented in SRS patients (Duncan et
al. 1990).
3.3. Strategies for identifying disease
genes
3.3.1. Functional cloning
In a functional cloning approach one
utilises knowledge about the
biochemical basis of a hereditary
disorder in the identification of a disease
gene. Either a purified protein or a
functional gene assay must be available.
If the protein can be isolated and the
amino acid sequence determined, one
can design partially degenerate
oligonucleotides for cDNA library
screening. Factor VIII gene, in which
mutations cause hemophilia A, was
identified using this method (Gitschier et
al. 1984).
Alternatively, the amino acid
sequence can be used to raise specific
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antibodies against a protein or a
fragment of it. The antibodies can be
used to immunoprecipitate
polyribosomes containing mRNA of an
unidentified gene. The mRNA is isolated
and converted to cDNA, and a specific
cDNA clone is isolated from a cDNA
library. This approach was applied in the
identification of the phenylketonuria
gene (Robson et al. 1982).
If the phenotype of a disease can be
evaluated or measured from a cell
culture and the defective gene product is
unknown one can use functional
complementation assays.
In the process of microcell mediated
chromosome transfer (Cuthbert et al.
1995) all 22 autosomes and the X
chromosome, one at a time, are
incorporated into the genome of patient
fibroblasts. The rescued phenotype of
the hybrid fibroblast line determines the
chromosomal localisation of the
defective gene, which can be further
defined by introducing deleted versions
of the chromosome.
This method was applied in the
cloning of the Leigh syndrome (LS)
gene (Zhu et al. 1998). LS is a severe
neurodegenerative disorder associated
with systemic cytochrome c oxidase
(COX) deficiency, which can be
measured from cell culture extracts (Zhu
et al. 1998).
3.3.2. Positional cloning
Positional cloning implies identifying a
gene on the basis of its chromosomal
location (Collins 1992, 1995). The
number of inherited disease genes
identified by positional cloning has been
rapidly increasing during the last few
years. By the year 1998 altogether 107
inherited disease genes were identified
by pure positional cloning
(http://genome.nhgri.nih.gov/clone/). As
the Human Genome Project (HGP)
proceeds, the pure positional cloning
approach will be less frequently needed
and the positional candidate gene
approach will be applied (Collins 1995).
In the initial assignment of a disease
locus comparative genomic
hybridisation (CGH), loss of
heterozygosity (LOH) analysis,
chromosomal aberrations, and linkage
analysis can be utilised. CGH and LOH
analysis can only be applied in the
identification of cancer genes, whereas
chromosomal aberrations and linkage
analysis can also be applied in the
identification of a disease gene




(CGH) allows the mapping of novel
oncogenes and tumour suppressor (TS)
genes (e.g. Hemminki et al. 1997;
reviewed by Knuutila et al. 1998, 1999).
CGH is a molecular cytogenetic method
first reported by Kallioniemi et al.
(1992) permitting screening of tumour
genome for genetic alterations, gains or
losses of DNA sequences.
Labelled tumour DNA and normal
reference DNA are hybridised in a
competing manner onto normal
metaphase preparations. DNA copy
number changes must be present in 50%
of tumour sample cells in order for CGH
to detect them (Kallioniemi et al. 1994).
The sensitivity of the method is
dependent on the size and magnitude of
the copy number change. On the
average, CGH detects DNA copy
number changes of 5-10 Mb
(Kallioniemi et al. 1994). From there on
conventional tools of physical mapping
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and mutation analysis are needed for the
final identification of a cancer gene.
3.3.2.2. Loss of heterozygosity analysis
TS genes inhibit cell proliferation and
their reduced transcription or deletion is
known to be involved in malignant
transformation (Knudson 1971, Friend et
al. 1988). Locations for TS genes can be
identified by loss of heterozygosity
(LOH) analysis. Commonly the first
mutation in a TS gene is a point
mutation, whereas the second mutation
involves a loss of a part of a
chromosome. As a result of the second
mutation one allele is lost at any DNA
marker analysed close to a TS gene.
Thus, an individual heterozygous at a
locus is mutated into a hemizygote in
tumour tissue. The screening of paired
blood and tumour DNA samples with
markers covering the whole genome
provides a method for identifying TS
gene loci (Vogelstein et al. 1989, Smith
et al. 1992)
3.3.2.3. Chromosomal aberrations
In a process of identifying a gene for a
hereditary disorder one can take
advantage of chromosomal aberrations.
If e.g. a balanced translocation is
detected in a karyotype of a patient, it
can be hypothesised that the gene
disrupted during the translocation is the
causative gene for the disorder. Thus, the
characterisation of the chromosomal
breakpoint regions pinpoints the critical
gene region. Subsequently, conventional
tools of physical mapping, gene
identification, and mutation analysis are
used.
This approach has been successfully
exercised in identifying several X-linked
genes such as the Duchenne muscular
dystrophy gene (Monaco & Kunkel
1988) and the anhidrotic ectodermal
dysplasia gene (Srivastava et al. 1996,
Kere et al. 1996). This approach depends
on rare events, which are not found for
every disease gene identification project.
3.3.2.4. Linkage analysis
3.3.2.4.1. Basic concept
Linkage analysis offers a general
approach for gene mapping. Any
monogenic disorder locus can be
assigned providing a sufficiently large
panel of families and markers is
available.
Linkage analysis locates a gene by its
proximity to another locus on the same
chromosome. Linkage analysis is based
on recombinations that arise as a result
of crossing-over events taking place
during pachytene stage of meiosis I of
germline cells. The arms of two
homologous chromosomes tend to cross
over allowing homologous
chromosomes to exchange chromosomal
material. Recombinations increase
enormously the potential genetic
diversity of gametes. Two loci far apart
on a chromosome will most likely be
separated in crossing-over, whereas two
loci located close together on a
chromosome will most likely stay
together after a crossing-over event.
The frequency of recombination
between two loci can be used as a rough
measure of their distance. The distance
between two loci is defined in units of
centiMorgans (cM). If two loci are 1 cM
apart, there is a 1% chance of
recombination between these loci as the
chromosome is passed from one
generation to another.
The relation of genetic distance to
physical chromosomal distance is not
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linear. Firstly, recombination in
autosomes is more frequent in females
than males. Secondly, recombination
frequency varies in different parts of the
chromosome and seems to be greater at
telomeres than near the centromere. On
the average 1 cM corresponds to 1 Mb.
(Morton 1955, Ott 1991).
3.3.2.4.2. Lod score
Basic concept
The proportion of recombination, out of
all opportunities for recombination, is
called the recombination fraction,
denoted by the Greek letter theta (θ). For
unlinked gene loci, the recombination
fraction is equal to 0.5, while for linked
loci it is less than 0.5.
The lod score method is a likelihood-
based analysis testing whether an
observed recombination fraction
between two loci is significantly smaller
than 0.5. The lod score (Z) is calculated
as a log10 of the ratio: likelihood of
linkage at θ/likelihood of no linkage. In
practice, this ratio is computed for
several values of θ. The most likely
distance between the loci is the θ value,
at which the highest positive lod score is
obtained.
Positive lod scores suggest the
presence of linkage, whereas negative
lod scores do the opposite. A positive
lod score of 3 or greater is considered
significant evidence for linkage, since it
indicates 10-3 or 1:1000 odds that the
linkage observed did not happen by
chance. A lod score less than –2 is
commonly considered as a significant
evidence against linkage, since it
indicates 1:100 odds against linkage.
(Morton 1955, Gelehrter and Collins
1990, Ott 1991).
Parametric and non-parametric method
The standard lod score analysis is called
parametric linkage analysis since it
requires a precise mode of inheritance,
gene frequencies, and penetrance for
each genotype. Parametric linkage
analysis is suitable for localising disease
genes for Mendelian disorders. In two-
point linkage analysis one uses
phenotype data and allele data at one
marker locus for calculating lod scores,
whereas in multipoint linkage analysis
allele data from several loci are
simultaneously considered improving
the efficiency of analysis.
Non-parametric linkage analysis is a
model-free method, which does not
require knowledge about the inheritance
pattern of the disease. Non-parametric
methods ignore unaffected people, and
look for alleles that are shared by those
affected. Sib pair analysis uses the non-
parametric method within nuclear
families, whereas in association studies
the non-parametric method is used at the
population level. Non-parametric
methods are used for searching genes
predisposing to multifactorial diseases
like diabetes (Mein et al. 1998).
3.3.2.4.3. Computer programmes
Presently, there are several computer
programmes available for calculating the
likelihood of linkage. LINKAGE
(Lathrop et al. 1984, Ott 1995) is one of
the most widely used programme
packages consisting of a series of
programmes for maximum likelihood
estimation of recombination rates and
analysis of genetic risks.
GENEHUNTER (Kruglyak et al.
1996) can be used for e.g. parametric
linkage analysis, non-parametric
multipoint linkage analysis, haplotype
reconstruction, and sib pair analysis.
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A multilocus linkage analysis
programme VITESSE (O'Connell &
Weeks 1995) uses a novel set-recoding
scheme to recode each person's genotype
and “fuzzy inheritance” to infer
inheritance relations accelerating the
calculation.
MAPMAKER/HOMOZ (Kruglyak et
al. 1995) also allows rapid multipoint
analysis, including homozygosity
mapping. MAPMAKER/HOMOZ can
be used in small consanguineous
pedigrees with missing genotype
information. The limiting factor in the
analysis is the relatively small number of
meiosis (about 16) that can be analysed
at a time.
Simulation programmes e.g. SLINK
(Weeks et al. 1980, Ott 1989), which is
based on the LINKAGE programme, and
SIMLINK (Boehnke 1986) can be used
to estimate whether it is possible to
localise a disease gene based on linkage
analysis in a given set of families.
3.3.2.4.4. Polymorphic markers
The first polymorphic markers used for
linkage analysis were restriction
fragment length polymorphisms (RFLPs)
(Botstein et al. 1980). RFLPs are often
based on a single nucleotide variations at
restriction sites. Initially, restriction
digestion and Southern blotting were
used in the analysis of RFLPs making
the method laborious. Nowadays RFLPs
can be typed by polymerase chain
reaction (PCR).
Polymorphism information content
(PIC) is a measure of the
informativeness of a polymorphic
marker. The number of alleles and the
allele frequencies determine the PIC
value. A marker with a PIC value of 0 is
never informative, whereas a marker
with a PIC value of 1 is always
informative and most likely reveals
whether a gamete is a recombinant or
not.
The PIC value of the RFLPs is low,
as the markers usually have only two
alleles. The RFLPs can also be caused
by variations in the number of short
repeated sequences. They are referred to
as variable number of tandem repeats,
VNTRs (Nakamura et al. 1987). The
analysis of VNTRs was initially based
on restriction digestion and Southern
blotting. The VNTRs are less frequently
detected in the human genome than
single nucleotide variations at restriction
sites, but their PIC value is usually high.
The PCR method was introduced in
the mid 1980´s (Mullis et al. 1986)
providing an efficient method for
genotyping short tandem repeats (STRs),
also called microsatellite markers (Litt &
Luty 1989, Weber & May 1989). The
microsatellite markers are prevalent and
the PIC values are frequently high. They
account for about 0.5% of the human
genome and occur approximately once
in every 30 kb (Strachan and Read
1996). Several CA-repeat microsatellite
maps have been published (Weissenbach
et al. 1992, Gyapay et al. 1994, Murray
et al. 1994, Dib et al. 1996).
Single nucleotide polymorphism
markers (SNPs) represent the latest
generation of markers used for
genotyping. An SNP is defined as a
position at which two alternative bases
occur at appreciable frequencies (Collins
et al. 1997). SNPs are not prone to
spontaneous mutations. The PIC values
of SNPs are low compared with
microsatellites.
Consequently, at least 2 to 5 times
more SNPs will be required to achieve
the same power as with microsatellite
markers in pedigree based mapping
studies (Kruglyak 1997). Furthermore,
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the higher density of markers will also
require a very high resolution physical
map to assure the proper order of
markers. This probably will not be
accomplished until the full sequence of
the human genome is known.
3.3.2.4.5. Family material
Families with two or more affected
individuals are informative in a
conventional linkage study, as they
provide the possibility to know which
alleles are inherited from which parent,
and each meiosis can be scored as
recombinant or nonrecombinant.
The enormous number of
polymorphic markers and the automated
genotyping systems (Ansorge et al.
1987, Karger 1996, Perlin et al. 1995)
currently available allow effective
genotyping. Actually, the main
limitation in a high-throughput
microsatellite genotyping is the required
manual editing of allele calls (Pálsson et
al. 1999).
This development has reduced
significantly the number of families
needed for a linkage study. Diastrophic
dysplasia (DTD) was one of the first
mapped disease loci of the diseases of
the Finnish disease heritage. The DTD
locus was mapped by linkage analysis
with 13 multiplex families (Hästbacka et
al. 1990), whereas more recently Cohen
syndrome (Tahvanainen et al. 1994),
Meckel syndrome (Paavola et al. 1995),
and Muscle-eye-brain disease (Cormand
et al. 1999) loci were assigned by
linkage analysis with only five, five, and
four multiplex families, respectively.
Furthermore, the infantile-onset
spinocerebellar ataxia locus was mapped
with samples from only four patients but
a different statistical approach,
homozygosity mapping, was utilised
(Nikali et al. 1995).
3.3.2.5. Linkage disequilibrium
and haplotype analysis
Concept of linkage disequilibrium
Linkage disequilibrium and haplotype
analysis can be used to refine the initial
disease locus assignment in isolated
populations.
The majority of patients suffering
from a hereditary disease in an isolated
population share the same mutation
inherited from a common ancestor.
Usually, the affecteds also share alleles
at marker locus close to the disease gene.
This non-random association of alleles at
a linked locus is called linkage
disequilibrium (LD). LD is seen when
apparently independent chromosomes
originate partly from the same ancestral
chromosome. The extent of LD
decreases exponentially with time, at a
rate proportional to the recombination
rate (Rannala & Slatkin 1998).
Families with only one affected
individual, and data about the historical
recombinations can be used in LD
analysis increasing markedly the number
of exploitable meiosis compared to
linkage analysis.
Haplotype analysis
When a disease mutation and marker
loci lie close to each other in the
genome, a certain set of alleles of the
markers will co-segregate with the
disease mutation, and the disease
phenotype, constituting a haplotype. The
“ancestral” haplotype associated with the
original founder mutation will be broken
by historical recombinations that
occurred during the centuries following
the introduction of the mutation into the
population.
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If a long period of time has elapsed
since the origin of the mutation, the
haplotype will be broken by several,
random historical recombinations, and
subsequently, the length of the shared
haplotype decreases (Fig. 3).
When analysing haplotype data, it
must be remembered that markers, in
particular microsatellites, do undergo
spontaneous mutations leading to false
interpretations. The high heterozygosity
of a marker locus is associated with an
increased risk of spontaneous mutation
at the locus (Jeffreys et al. 1988,







The mutation is marked with a black point, polymorphic markers are indicated
with bold vertical lines, and the shaded area represents the shared haplotype in
the disease chromosomes. The founder chromosome is shown above, and below
that the disease chromosomes after generations (g) indicating the shortening of
the shared haplotype. If the mutation is new the shared haplotype is detected over
a longer region than in the case of an older mutation.
(Adapted from de la Chapelle et al. 1994)
new mutation
old mutation
Fig. 3 The extent of linkage disequilibrium.
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LD and statistical formulas
Several statistical formulas for
estimating the distance between a
mutation and a marker locus on the basis
of LD have been reported (Hästbacka et
al. 1992, Lehesjoki et al. 1993,
Terwilliger 1995, Kaplan et al. 1995,
Xiong & Guo 1997, Rannala & Slatkin
1998).
Hästbacka et al. (1992) and Lehesjoki
et al. (1993) applied the Luria-Delbrück
formula originally designed for the
analysis of bacterial cultures (Luria &
Delbrück 1943) to study LD in the
Finnish population. This analysis allows
estimation of the recombination fraction
between a disease locus and a marker,
the degree of allelic homogeneity among
disease causing alleles, and the mutation
rate for nearby genetic markers.
Since the formula expects the
population to grow exponentially with
random mating, and some of the
parameters have to be estimated
according to the population history, the
resulted estimates must be evaluated
cautiously. The Luria-Delbrück analysis
works well for recessive disorders that
are primarily due to a single disease-
causing mutation (Jorde 1995).
Terwilliger presented in 1995 a new
likelihood-based approach to test LD.
This method allows for multiple
polymorphic marker loci to be studied
simultaneously without reducing the
analysis to a diallelic situation. Poorly
matched case and control subjects may
present a problem in association studies,
as is reported in other approaches as
well. While studying Mendelian
disorders this problem is accounted for
by treating non-transmitted alleles as the
control subjects and transmitted alleles
as the case subjects. Also this method
has been applied in several disease gene
identification projects (Nikali et al.
1995, Virtaneva et al. 1996, Aaltonen et
al. 1997).
3.3.2.6.Physical mapping
After a disease gene locus has been
refined by genetic mapping one usually
initiates physical mapping of the region.
There are several methods for physical
mapping, which are usually applied
simultaneously. The most commonly
used methods are described below.
Radiation hybrids
Radiation hybrids (RH; Cox et al. 1990,
Gyapay et al. 1996) provide a possibility
for high-resolution physical mapping
without a contig of clones. After fusing
irradiated donor cells with recipient
rodent cells (e.g. hamster), a panel of
hybrid cell lines is produced. Typically,
PCR reactions are carried out on each
cell line of the panel using primers for an
EST, a sequence tagged site (STS), or a
polymorphic marker. Markers which are
close to each other will be retained in the
same cell line more often than markers
which are further apart. The resolution
of the radiation hybrid mapping is a
function of the donor fragment size,
which can be varied by altering the
radiation dose.
A contig of overlapping clones
A contig of overlapping yeast and
bacterial clones is an important tool in
the process of disease gene
identification. It is frequently
constructed using yeast artificial
chromosomes (YACs) (Schlessinger
1990, Burke et al. 1992), bacterial
artificial chromosomes (BACs) (Shizuya
et al. 1992), bacteriophage P1-based
cloning systems (P1s) (Sternberg et al.
1990, Pierce et al. 1992), P1-derived
artificial chromosomes (PACs) (Ioannou
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et al. 1994), and cosmids (Collins &
Hohn 1978).
The insert size of YACs ranges from
300 to 2000 kb. The YACs are
frequently chimeric and rearranged
making their usage laborious. A more
stable and non-chimeric cloning system
is provided by the BACs, P1s, and
PACs, which have an insert size range of
70-300 kb. The cosmid vectors are again
more unstable and have a 30% rate of
chimerism. Nevertheless, cosmid vectors
are suitable for applications requiring a
small fragment of human DNA (30-44
kb) at a time.
Due to the efforts of several genome
centers, e.g. Centre d'Etude du
Polymorphisme Humain (CEPH) and
Whitehead Institute Center for Genome
Research (WICGR), a contig of YACs
(Cohen et al. 1993, Chumakov et al.
1995) is usually available on the region
of interest. If not available, YACs, as
well as BACs, PACs, and cosmids can
be conveniently screened by
hybridisation or PCR from chromosome
specific or whole genomic libraries
(Shizuya et al. 1992, Ioannou et al.
1994).
STS content mapping
As a positive clone has been identified,
the end sequences of the cloned DNA
will be determined. A novel STS primer
pair is designed from the unique end
sequence. The presence of the STS in
other clones of the contig is tested by
PCR assay. Moreover, the STS can be
utilised to screen a clone library for
novel clones. This method is called STS
content mapping.
Pulsed-field gel electrophoresis
The sizes of YACs, BACs, and PACs
can be determined by pulsed-field gel
electrophoresis (PFGE) (Schwartz &
Cantor 1984). Based on the PFGE
analysis it is possible to estimate the size
of the entire contig of clones. PFGE is a
modification of agarose gel
electrophoresis. During a PFGE run the
relative orientation of the gel and the
electric field is periodically altered, so
that the DNA molecules are
intermittently forced to change their
conformation and direction of migration.
The time taken for a DNA molecule to
re-orient itself is size-dependent. PFGE
is able to size-fractionate DNA
fragments up to several megabases.
Fiber-FISH
The fiber-FISH method has been shown
to be a powerful method for contig
construction (e.g. Klockars et al. 1996,
Nikali et al. 1997). The fiber-FISH
method (Heiskanen et al. 1995) is a
modification of fluoresence in situ
hybridisation (FISH; Pinkel et al. 1986,
Lichter et al. 1988). Fiber-FISH enables
the ordering of overlapping and non-
overlapping clones and the estimation of
sizes of overlaps and gaps between
clones using clones of known
localisation and size as reference probes
in hybridisation. This way the size of the
entire contig of clones can also be
estimated.
The DNA fibers for fiber-FISH
analysis are derived from agarose
embedded proteinase K treated cells. A
piece of an agarose block is melted on a
microscopic slide, and the DNA fibers
are spread over the slide manually by
another slide. This easy and fast
preparation of the target for
hybridisation is one of the main
advantages of fiber-FISH. On the other
hand, some variability in the stretching
occurs between slides due to the manual
performance.
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The probe labelling, hybridisation, and
fluorescence microscopy are performed
as in a conventional FISH method
(Pinkel et al. 1986, Lichter et al. 1988).
Contig can be used for several purposes
The contig of yeast and bacterial clones
can be utilised for mapping genes, ESTs,
STSs, and polymorphic markers by PCR
assay.
Furthermore, the contig of clones
enables the isolation of novel
polymorphisms that are useful in the
refinement of the disease locus.
When required the genomic clones
can also be exploited for the
identification of expressed sequences
and genes (see 3.3.2.7.).
If the critical gene region is small
enough (<300 kb), it is feasible to
sequence the whole region. Large-scale
sequencing projects usually apply the
shotgun sequencing method (Venter et
al. 1998). Initially, the starting material,
a BAC or a PAC clone, is partially
digested with a rare-cutter enzyme. The
partially overlapping fragments are
shotgun-cloned into a suitable vector and
the overlapping clones are randomly
sequenced. The sequences are aligned by
computer programmes.
3.3.2.7. Identification of expressed
sequences
Novel expressed sequences can be
identified from genomic clones by
several methods of which the most
frequently employed are CpG island
identification, direct cDNA selection,
and exon amplification.
If the genomic sequence of the region
of interest is available, novel coding
sequences can be identified by
homology searches and exon prediction
programmes.
None of the methods is able to detect
all of the existing genes. To ensure as
many as possible of the genes to be
identified, usually several gene
identification methods are applied
simultaneously. At the end conventional
cDNA library screening is often needed
to construct the full length coding
sequence of the gene.
CpG island identification
CpG islands (Bird 1986) are short
regions (<1 kb) of genome with high GC
content (>60%). In humans
approximately 56% of the genes are
associated with CpG islands, including
housekeeping and widely expressed
genes, but leaving a substantial number
of genes out of reach of the method. The
CpG islands often have recognition sites
for rare-cutter restriction endonucleases,
and thus they can be identified by
restriction mapping (Larsen et al. 1992).
Direct cDNA selection
In direct cDNA selection a genomic
clone or a part of it is PCR amplified,
bound to a solid support, and hybridised
to a mixture of PCR amplified cDNAs,
e.g. a cDNA library (Lovett 1994).
Several consequent hybridisations are
carried out to increase the yield and
specificity of the target cDNA. In the
hybridisations repetitive DNA sequences
in the genomic clone have to be
carefully blocked. The expression level
of a gene, the length of the exons, and
the selection of cDNA library influence
the feasibility of isolating it by direct
cDNA selection.
Exon amplification
The majority of mammalian genes have
more than one exon. This feature of a
gene is exploited in the exon
amplification method (Buckler et al.
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1991, Church et al. 1994, Church &
Buckler 1999).
A genomic fragment of interest (e.g. a
cosmid) is cloned into a specific exon-
amplification vector including a SV40
promoter and two vector exons between
which the target genomic fragment is
cloned. The construct is transfected to
e.g. COS cells.
The process of transcription initiates
from the SV40 promoter of the vector,
and the produced pre-RNA molecule
undergoes splicing by the RNA splicing
machinery of the host cell.
The mature RNA molecule consists
of the vector exons in both ends and of
the captured exon(s) in between. This
“fusion” RNA is isolated, and
subsequently cDNA is synthesised.
Vector-exon-specific PCR primers are
utilised for the amplification of the
trapped exon/s. As the method is based
on splicing it is able to identify genes
with at least two exons.
Homology searches
Similarity search programmes like
BLAST (Basic Local Alignment Search
Tool), Gapped BLAST and PSI-BLAST
can be used to explore all the available
sequence databases (Altschul et al. 1990
and 1997) for homology of the sequence
of interest with known nucleotide
sequences or proteins.
The programmes compare the input
sequence in six reading frames against
the databases. The matches to previously
known genes, cDNAs, and ESTs are
presented in the output according to their
probability. Any significant gene,
cDNA, or EST match, whether human or
non-human in origin, indicates a gene
associated sequence: a functional gene, a
pseudogene or a gene fragment.
The coding DNA sequences are often
well conserved between species. Many
human genes show significant matches
to the genes of evolutionarily distant
species such as Saccharomyces
cerevisae, Drosophila melanogaster and
Caenorhabditis elegans. As most of the
gene and protein families have already
been identified, it is very rare to find a
novel gene without any homology to
previously identified gene(s).
Exon prediction
There are several exon prediction
programmes available, e.g. GeneMark
(Isono et al.1994), Genie (Henderson et
al. 1997), GRAIL 1a & 2 (Gene
Recognition and Assembly Internet Link;
Milanesi et al. 1993), MZEF (Michael
Zhang's Exon Finder; Zhang 1997), and
Xpound (Thomas & Skolnick 1994).
Some of the programmes are based
on identifying internal exons by looking
for conservative sequences at the splice
acceptor, splice donor, and branch sites
as well as looking for long open reading
frames (ORFs). Some prediction
programmes look for additional
structural gene elements like promoter
sites, translation sites, polyadenylation
signals, and stop codons.
The programmes currently available
locate at best 80% of the internal coding
exons, and 5% of the predictions do not
overlap a real exon (Claverie 1997).
Genotator (Harris 1997) presents a
new “workbench” for sequence analysis.
It runs five different gene-finding
programmes (GRAIL, GeneFinder,
Xpound, GeneMark, and Genie), three
homology searches (repetitive elements,
ESTs, and translated coding regions),
and searches for promoters, splice sites,
and ORFs.
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3.3.2.8.Mutation screening
Mutation screening is the final step in a
positional cloning project. A candidate
gene or a part of it is tested for sequence
variations in a set of patients and control
samples. The most commonly used
mutation screening methods are briefly
described.
Methods for mutation screening
Using Southern blot analysis (Southern
1975) size-fractionated DNA fragments
of patients and controls are compared
after hybridisation with a gene-specific
probe. This method is able to detect only
large genomic rearrangements: deletions,
insertions, and duplications.
Northern blot analysis is a variant of
Southern blotting, in which the target is
RNA instead of DNA (see also 3.4.).
Northern blot analysis is able to detect
mutations that alter the level of
expression or the size of transcript.
Single-strand conformational
polymorphism (SSCP) analysis (Orita et
al. 1989) is based on a tendency of
single-stranded DNA to fold up
according to the DNA sequence in a
non-denaturing gel. Any variation in
DNA sequence is seen in the gel as a
mobility shift. SSCP analysis is suitable
for relatively short PCR fragments (<250
bp). To maximize differential migration
of DNA fragments in SSCP it is crucial
to optimise the experimental conditions.
Thus, not surprisingly, the sensitivity of
SSCP for mutation detection has been
reported to range from 30% to 100%
(Michaud et al. 1992, Sarkar et al. 1992,
Claustres et al. 1993, Sheffield et al.
1993).
Chemical cleavage of mismatches
(CCM) (Moser & Dervan 1987, Grompe
et al. 1989) detects mismatches,
variations in DNA sequence, by a series
of chemical reactions. This highly
sensitive method can be applied to
sequences of up to 1 kb. Since the
necessary reagents are toxic the usage of
CCM is inconvenient.
Denaturing gradient gel
electrophoresis (DGGE) (Cariello &
Skopek 1993) is based on migration of
DNA duplexes on a chemical or a
temperature gradient gel. Migration
continues until the DNA duplexes reach
a position in the gel where the strands
melt and separate, after which the
denatured DNA does not migrate much
further. The melting temperature of the
fragment is determined by the DNA
sequence. Primers with long stretches Gs
and Cs, that is GC-clamps, are used to
maximize the sensitivity of the method
for mutation detection. The need for GC-
clamps in the primers makes DGGE an
expensive procedure.
If a difference in Southern blotting,
Northern blotting, SSCP, CCM, or
DGGE is detected between the patients
and the control individuals, one has to
ultimately characterise the variation at
nucleotide level by sequencing. As the
sequencing facilities have improved
during the last years, frequently one uses
direct sequencing for primary mutation
screening.
Mutation or polymorphism?
A sequence variation may be a
polymorphism or a disease causing
mutation.
A variation can be considered to be a
disease causing mutation if one finds in
the same gene at least two separate
variations in different families affected
by the same disease. A disease causing
mutation also changes the amino acid
code. If only one amino acid is changed
its significance can be evaluated by
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studying whether the amino acid is
highly conserved between species.
Highly conserved amino acids are
functionally important and sequence
variations abolishing them are likely to
be mutations.
Additionally, in recessive disorders
the variation should not be identified in a
homozygous form in unaffected control
individuals, and the heterozygous carrier
frequency should not exceed the
frequency expected by the disease
incidence in the population.
The localisation and type of a
sequence variation affects the probability
of it being a disease causing mutation.
Deletions, insertions, and
duplications in an exon are likely to be
deleterious especially when causing a
frameshift of the open reading frame
(ORF). On the other hand, such
variations are commonly detected in
intronic sequences as polymorphisms.
A single nucleotide variation that
causes a premature stop codon in an
exon is likely to be deleterious, whereas
if the consequence is merely a change of
an amino acid, it may be a
polymorphism as well as a disease
causing mutation (see above). A single
nucleotide variation in an intron is most
likely a polymorphism, unless it
produces a cryptic splice site or is
localised in the consensus sequence of
the splice acceptor or splice donor site.
On one hand unstable trinucleotide
repeats located in 5´ and 3´ untranslated
regions and coding regions are known to
be associated with at least ten inherited
neurological disorders (Ashley &
Warren 1995, Warren 1996). On the
other hand intronic microsatellite repeats
(1-4 bps) are frequent and polymorphic.
Interestingly, an intronic GAA triplet
repeat expansion causes Freidreich´s
ataxia (Campuzano et al. 1996).
A minisatellite expansion (12 bps) in
the promoter region of the cystatin B
gene, was reported to underlie EPM1, a
recessively inherited neurodegenerative
disorder (Lalioti et al. 1997, Virtaneva et
al. 1997), introducing a novel type of
human mutation.
3.4. Analysing gene expression
Gene expression studies provide
valuable information about the function
of a gene, as they reveal tissues, cell
types, and developmental stages at
which a gene is functioning.
Gene expression analysis is also
useful in evaluating candidate genes. In
a multi-organ phenotype the causative
gene should be expressed ubiquitously
(e.g. The Finnish-German APECED
Consortium 1997). However, in a
phenotype restricted to a particular tissue
the underlying gene may be expressed
only in the affected tissue (e.g. Höglund
et al. 1996) or in most or all of the tissue
types (e.g. Pennacchio et al. 1997).
Northern blot analysis is the basic
method for studying gene expression.
Either total RNA or mRNA is
fractionated according to size using
denaturing gel electrophoresis. RNA is
subsequently transferred to a membrane
which is hybridised with a labelled
probe. If the studied gene is a single
copy gene, a cDNA clone can be used as
a probe. If the gene is a member of a
gene family, the probe should be a PCR
or a RT-PCR fragment from a gene
sequence that is not conserved between
family members. A Northern blot
membrane consisting of different tissue
types reveals the gross expression
pattern, but may also detect different
isoforms of RNA produced by
alternative splicing.
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Reverse-transcriptase PCR (RT-PCR)
can also be used for studying different
isoforms of RNA as well as for a rough
quantitation of gene expression (Pykett
et al. 1994). RT-PCR is a version of the
standard genomic PCR reaction. First
one isolates total or mRNA, and then
converts it to cDNA using reverse
transcriptase enzyme. The cDNA is used
as a template for a PCR reaction with
exon-specific primers. Extra
amplification products in addition to the
expected products may represent
different isoforms of the RNA.
3.5. RING finger-B-box-coiled-coil
proteins
In the positional cloning project
described in this thesis mutations in a
novel gene encoding a RING finger-B-
box-coiled-coil (RBCC) protein were
identified in MUL patients. In this
chapter the current knowledge about
RBCC proteins is reviewed.
The RBCC family consists of proteins
that have a RING finger, and one or two
B-box motifs followed by a coiled-coil
domain (Freemont 1993, Saurin et al.
1996; Fig. 4a).










Fig. 4a Schematic representation of RING finger, B-box, and coiled coil domains in RBCC proteins.
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RING finger proteins
The RBCC proteins constitute a
subgroup in the family of RING finger
proteins. The RING finger motif was
found in the sequence of the human
RING1 (Really Interesting New Gene 1)
gene proximal to the MHC region on
chromosome six (Hanson et al. 1991).
The RING finger is a cysteine rich motif,
defined by the following sequence:
Cys1-X2-Cys2-X(9-27)-Cys3-X(1-3)-His1-
X2-Cys4-X2-Cys5-X(4-48)-Cys6-X2-Cys7,
where X can be any amino acid.
The RING finger motif uses eight
ligands, Cys and His residues, to bind
two zinc atoms in a unique cross-brace
system (Borden et al. 1995a). In this
system the first and third pairs of metal-
binding ligands share one zinc atom and
the second and fourth pairs share the
second zinc.
RING finger proteins have been
identified from human to plants to yeast
to viruses but interestingly not in
prokaryotes (Saurin et al. 1996).
Presently, there are several hundred
cDNAs encoding RING finger proteins
in the GenBank database. BRCA1, the
breast cancer predisposing gene, is one
of the well-known RING finger genes
(Wu et al. 1996).
Recent studies have shown that the
RING finger domain plays an important
role in mediating specific ubiquitylation
events (Waterman et al. 1999, Yokouchi
et al. 1999, Joazeiro et al. 1999, Lorick
et al. 1999). It has been suggested that
all RING proteins act as E3 ubiquitin
protein-ligases involved in a variety of
biological processes (Freemont 2000).
This is in keeping with the functional
diversity of the RING finger family
proteins.
Nevertheless, most RING finger
proteins have either unknown functions
or functions not obviously related to
ubiquitination. It has been proposed that
RING-mediated ubiquitination targets
the RING containing protein or
associated protein for degradation in a
regulated manner (Lorick et al. 1999).
B-box motif
A RBCC protein contains, C-terminal to
the RING finger domain, one or two B-
box motifs (Freemont 1993; Fig. 4a),
which represents another cysteine-rich
motif. The consensus motif of a B-box
can be defined as Cys1-X2-His1-X7-
Cys2-X7-Cys3-X2-Cys4-X5-His2-X2-
His3 (Fig. 4b).
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Protein
RPT-1 C AQHG EKL RLFCRKDMMVICWLCERSQE H RGH
SS-A/Ro C AVHG ERL HLFCEKDGKALCWVCAQSRK H RDH
RET C EKHR EPL KLYCEEDQMPICVVCDRSRE H RGH
xnf7 C SEHD ERL KLYCKDDGTLSCVICRDSLK H ASH
T18 B2 C PFHKKEQL KLYCETCDKLTCRDC QLLE H KEH
PML B2 CSNPNHRTPTLTSIYCRGCSKPLCCSCALLDSSHS ELKC
PML B1 C TRCK ESA DFWCFECEQLLCAKCFEA HQW FLKH
T18 B1 C TSCEDNAEANGFCVECVEWLCKTCIRA HQRVKFTKDH
MUL C ENHH EKL SVFCWTCKKCICHQCALWGGMH GGH
Fig. 4b
Alignment of proteins that contain the B-box motif (adapted from Reddy et al.).
B1 and B2 refer to the two B box motifs found in T18 and PML. The bold typed letters
represent the conserved Cys (C) and His (H) residues. The alignment of RPT -1, SS-
A/Ro, RET , xnf 7, T18, PML, and T18 was obtained automatically using the program
AMPS with PAM matrix of 250. The MUL amino acid sequence was aligned.
Although there are seven conserved
ligands, Cys and His residues, it has
been shown that only one zinc atom is
bound per B-box (Borden et al. 1993,
Bellini et al. 1995). According to the
existing opinion the zinc-binding atoms
of the B-box are: Cys1, His1, Cys4, and
His2 (Borden et al. 1995b). The rest of
Cys and His residues have been
suggested to be conserved for functional
reasons; they seem to be important in
protein-protein interactions (Cao et al.
1997).
Unlike the RING finger, the B-box
motif is highly conserved between
family members (Fig. 4b). Furthermore,
the sequence spacing between the RING
finger and the first B-box is highly
conserved (31-39 amino acids; Fig. 4a).
This conservation suggests that RING
and B-box domains may interact,
forming an integrated fold. The second
B-box is followed closely (5-8 amino
acids) by a coiled-coil domain.
Coiled-coil domain
The coiled-coil domain is a predicted
secondary structure - a bundle of α-
helices that are wound into a superhelix
(Lupas 1996a). The coiled-coils have a
distinctive, repetitive pattern of
hydrophobic and hydrophilic residues
called the heptad repeat.
The long heptad repeats can be easily
picked up by eye. For the detection of
short heptad repeats at least two
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computer programmes are available via
the world wide web which take into
account the residue distribution of
known coiled-coils (Coils, Lupas 1996b;
Paircoil, Berger et al. 1995).
Originally, the coiled-coil was
described (Pauling & Corey 1953, Crick
1953) as the main structural element of
fibrous proteins as keratin, myosin, and
fibrinogen. It was only until the late
1980´s when coiled-coil proteins were
identified as the dimerization element in
the leucine zipper proteins (Landschulz
et al. 1988).
In the 1990´s several transcriptional
activators with short coiled-coils of two
to five heptads have been shown to
mediate dimerization,
heterodimerization, and even to bind to
the DNA (reviewed by Lupas 1996a).
Functions of RBCC proteins
The current members of the RBCC
family have variable subcellular
locations and functions. The RBCC
proteins are thought to be involved in
protein-protein and/or protein-nucleic
acid interactions and in the formation of
multi-protein complexes (Borden &
Freemont 1996).
The RBCC family includes putative
transcription factors, like the Xenopus
nuclear factor (XNF7) (Borden et al.
1993), and the TIF proteins
(transcriptional intermediary factors)
TIF1α (Le Douarin et al. 1998) and
TIF1β (Chang et al. 1998).
Interestingly, three RBCC genes, ret
(Takahashi et al. 1988), pml as pml-rara
(Borden et al. 1996), and t18 (Le
Douarin et al. 1995) have transformation
potential when found as translocations in
human and mice. In all of these fusions
the zinc-finger and coiled-coil domains
are retained.
Another RBCC member, SS-A/Ro, is
a ribonucleoprotein and an autoantigen
in patients with systemic lupus
erythematosus and Sjögren syndrome
(Chan et al. 1991).
RBCC proteins and human diseases
Familial Mediterranean fever (FMF) and
Opitz syndrome (OS) are the only
previously reported disorders in which
mutations in genes encoding RBCC
proteins are responsible for the primary
defect.
The recessively inherited FMF
characterised by dramatic episodes of
fever and serosal inflammation, is
caused by mutations in a novel RBCC
gene, called MEFV (The French FMF
Consortium 1997).
OS is a multi-organ disorder
primarily affecting midline structures,
and it was shown to be due to mutations
in X-chromosomal MID1 encoding the
RBCC protein midin (Quaderi et al.
1997).
Midin is associated with microtubules
throughout the cell cycle (Cainarca et al.
1999, Schweiger et al. 1999).
Furthermore, midin is shown to mediate
homodimerization and to exist in the
form of large protein complexes
(Cainarca et al. 1999).
Mutations found in OS patients are
reported to reduce the ability of midin to
bind microtubules. Instead, cytoplasmic
clumps are formed (Cainarca et al. 1999,
Schweiger et al. 1999). However, some
of the mutants still possessing RBCC
domain were shown to retain their ability
to homodimerize and form multiprotein
complexes (Cainarca et al. 1999).
AIMS OF THE PRESENT STUDY
34
4. AIMS OF THE PRESENT
STUDY
• To determine the chromosomal
localisation of the Mulibrey Nanism
(MUL) locus by linkage analysis.
• To refine the MUL locus by linkage
disequilibrium analysis.
• To cover the MUL region with a contig
of yeast and bacterial clones.
• To localise candidate genes to the MUL
region.







A total of 50 Finnish and 2 non-Finnish
MUL patients were studied. The
pedigrees of the Finnish multiplex
families are shown in Fig. 5. The
diagnosis of the MUL patients was based
on the diagnostic criteria summarised in
Table 2. The Finnish control individual
DNA samples were provided by the
Finnish Red Cross Blood Transfusion
Service. The 100 non-Finnish control
individual samples originated from
CEPH. All the samples were obtained
after informed consent.
5.2. DNA and RNA extraction
DNA was extracted from fresh or frozen
venous blood using the non-enzymatic
DNA extraction method (Sambrook et
al. 1989). For RNA extraction EBV
transformed lymphoblast cell cultures
were established. Total RNA was
extracted using the RNeasy RNA
extraction kit (Qiagen) according to the
manufacturer´s instructions. QuickPrep
Micro mRNA Purification Kit
(Amersham Pharmacia Biotech) was
used for the extraction of polyA RNA
according to the manufacturer´s
instructions.
5.3. Microsatellite marker analysis
In the genome-wide search for linkage,
240 CA-repeat markers originating from
Généthon were used covering the
genome in approximately 20 cM
intervals (Weissenbach et al. 1992,
Gyapay et al. 1994, Dib et al. 1996). The
PCR reactions were performed as
described previously (Weber & May
1989). The initial systematic screening
for linkage was carried out at Généthon,
Paris, using a non-radioactive
genotyping method (Vignal et al. 1993).
Several amplification products from the
same DNA sample, generated with
different primer sets, were pooled and
co-precipitated and co-electrophoresed
in a single lane of a 6% polyacrylamide,
50% urea sequencing gel. After transfer
to nylon membranes, hybridisation was
performed with peroxidase labelled PCR
primers. The alleles were detected using
a chemiluminescence based detection
system (ECL, Amersham Pharmacia).
In refining linkage, the following
Généthon markers were used:
D17S1799, D17S1607, D17S1606,
D17S1853, D17S1604, D17S1811,
D17S1855, and D17S948. Marker
D17S1290 originated from the
Cooperative Human Linkage Center
(CHLC). Markers 272a-CA, 272b-CA,
132-CA, 58-CA, and 52-CA were
identified by a CA-repeat isolation
protocol (see below), and marker 95-CA
was found in the end sequence of a PAC
clone (95i19). All these markers were
analysed by radioactive genotyping
method described previously (e.g.




The pedigrees of the six MUL
multiplex families that were





By the simulation programme SLINK
(Weeks et al. 1990, Ott 1989) the panel
of six multiplex families (Fig. 5) was
estimated to give an average lod score of
2.7 (θ=0.0) assuming a heterozygosity
value of 0.70 for the markers.
In the initial screening for linkage, the
films were scored for the presence or
absence of recombinations by comparing
familywise the alleles of affected
individuals in multiplex families.
Two-point linkage analyses were
carried out using the MLINK
programme of the LINKAGE package
OS/2-version 5.2 (Lathrop et al. 1984).
Multipoint linkage analysis was
performed with VITESSE (O´Connell &
Weeks 1995). Multipoint analysis was
carried out under the assumption of a
fixed order and fixed distances of the
eight marker loci included in the analysis
(Dib et al. 1996). Allele data for loci
D17S1811 and D17S1855 were
combined for the multipoint computation
analysis with VITESSE while the other
loci were considered separately. All
calculations were done assuming
complete penetrance and equal
recombination frequency in males and
females.
5.5. Linkage disequilibrium and
haplotype analysis
To test whether there is a single allele
with a significantly higher frequency on
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disease bearing chromosomes than on
control chromosomes, we used Fisher´s
exact test with a Bonferroni´s correction
for multiple testing (e.g. Hästbacka et al.
1992). The non-MUL bearing
chromosomes of the parents were used
as control chromosomes.
The Luria-Delbrück based calculation
(Hästbacka et al. 1992, Lehesjoki et al.
1993) was used to estimate the genetic
distance between the polymorphic
markers and MUL under the following
assumptions: the number of generations
(g) since "founding", i.e. the beginning
of spreading of the MUL mutation in the
population, was 10-100; the mutation
rate (µ) of the MUL locus was 5 x 10-6,
as the disease is rare world-wide; the
overall MUL gene frequency (q) was
0.005 based on the Hardy-Weinberg
equilibrium and the actual observed
incidence of 1:40 000 of the disease
phenotype in Finland (Lipsanen-Nyman
1986). Allelic excess was calculated by
the formula: pexcess=(paffected-pnormal)/(1-
pnormal), where p denotes allele
frequency. The theta value (θ) or
recombination between MUL and a
marker locus was calculated using the
formula pexcess=(1-µgq-1)(1-θ)g, where
(1-µgq-1) denotes the proportion of
MUL chromosomes carrying the same
ancestral mutation.
The significance of linkage
disequilibrium between the disease and
marker loci was also analysed using the
DISLAMB programme (Terwilliger
1995). This programme applies a
likelihood-based test for linkage
disequilibrium and has only one degree
of freedom, irrespective of the number
of alleles at any given marker. The
calculations are based on the parameter
λ, which expresses the proportion of the
increase of a certain allele in the disease
chromosomes, relative to its population
frequency. Confidence intervals for λ
were calculated for 1-lod units.
The putative haplotypes were
constructed manually, assuming a
minimum number of recombinations in
each family.
5.6. Construction of a contig of yeast
and bacterial clones
ESTs, STSs, and YAC clones that were
mapped between markers D17S957 and
D17S1604 by WICGR and CEPH were
utilised in the initial construction of the
YAC contig (Hudson et al. 1995, Dib et
al. 1996, Schuler et al. 1996;
http://www-genome.wi.mit.edu).
Individual YAC clones were cultured,
and total yeast DNA was extracted and
stored in agarose beads. The chimerism
of YAC clones was analysed by the
metaphase-FISH technique (Bray-Ward
et al. 1996), and clones mapping to only
17q22-q23 were used for further studies.
The presence of STSs and ESTs in the
YACs was confirmed by PCR
amplification.
The STSs and ESTs present in the
YACs were used for screening of PAC
and BAC libraries by PCR assay. PCR-
positive clones were picked and cultured
in 100 ml Terrific Broth media or 400 ml
Luria Bertani media, supplemented with
25 mg/ml of kanamycin (PACs)
(Ioannou et al. 1994) or 12.5 mg/ml of
chloramphenicol (BACs) (Shizuya et al.
1992). DNA was extracted using a
Plasmid Maxiprep (tip 500) kit®
(Qiagen) according to manufacturer's
instructions.
The end fragments of the PAC and
BAC clones were sequenced directly
from the clone DNA with SP6 and T7
vector primers. New STSs were
designed from the non-repetitive end
sequences using the Primer3 software
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(WICGR) and further used for the
screening of genomic libraries. The
localisation of STSs and ESTs in the
PAC/BAC contig was determined by
PCR amplification.
5.7. Isolation of novel microsatellite
markers
Novel CA-repeats were isolated from the
PAC and BAC clones using the
following procedures. The PAC DNA
was digested with Sau3A1 and ligated to
pGEM7, transformed into DH5α cells
and plated onto selective agar plates.
BAC DNA was digested with RsaI and
ligated to SmaI cut pUC18 vector




(Stratagene) and plated onto selective
agar plates.
The colonies were transferred onto
nylon filters (Hybond-N®, Amersham or
Magna Chart
®
, MSI) and hybridised
with a radioactively labelled (GT)16
oligonucleotide at +65 °C overnight.
After autoradiography, positive colonies
were selected, and DNA isolated using a
Plasmid Miniprep (tip 20) kit® (Qiagen),
or Wizard Plus Miniprep kit
® (Promega).
The inserts were sequenced with SP6
and T7 vector primers. Oligonucleotide
primers flanking the CA-repeats were
selected with Primer3 software
(WICGR).
5.8. Fluorescence in situ hybridisation
The metaphase chromosome targets
were achieved by culturing human
peripheral blood lymphocytes according
to standard protocols (Lemieux et al.
1992, Tenhunen et al. 1995). Agarose
embedded lymphocytes were used as a
source of free DNA fibers according to
the method described previously
(Heiskanen et al. 1994, 1996). All PAC
and BAC clones used for the FISH
experiments were labelled with biotin
11-dUTP (Sigma) and digoxigenin 11-
dUTP (Boehringen Mannheim) by nick
translation according to standard
protocols.
The FISH procedure was carried out
as described previously (Pinkel et al.
1986, Lichter et al. 1988, Aaltonen et al.
1997). Briefly, the hybridisation mixture
contained 50% formamide and 10%
dextran sulfate in 2xSSC. Repetitive
sequences were suppressed with 10-fold
excess of Cot-1-DNA (BRL). After
overnight incubation at +37 °C the slides
were washed at +44 °C three times in
50% formamide and 2xSSC, twice in
2xSSC, and once in 0.5xSSC. The slides
were counterstained with DAPI (Sigma).
A multicolor image analysis was used
for acquisition, display and quantitative
analysis of fiber-FISH as described
elsewhere (Heiskanen et al. 1996,
Aaltonen et al. 1997).
5.9. Estimation of clone insert sizes by
pulsed-field gel electrophoresis
NotI-digested BAC or PAC DNA was
separated in 1% agarose using a work-
shop made pulsed-field gel
electrophoresis apparatus designed
according to the principles described by
Chu et al. (1986). The electrophoretic
conditions were 120 V, 60 s pulse time
for 48 h at 16 °C. The fragments were
visualised by staining the gel with
ethidium bromide and their sizes were




5.10. Mutation detection and
screening
5.10.1. Sequencing
The PCR primers for the mutation
analysis of PNUTL2 were designed from
the genomic sequence of a BAC clone,
hRPK.112_H_10 that revealed the
genomic organisation of PNUTL2. DNA
was used as template for PCR
amplification. The PCR primers for the
mutation analysis of KIAA0898 were
designed from the cDNA sequence, and
subsequently the cDNA was used as
template for PCR.
The purified PCR products (PCR
Purification Kit, Qiagen) were
sequenced using the PCR primers. Either
the ABI PRISM Dye Terminator or the
ABI PRISM Rhodamine cycle
sequencing kit (Perkin-Elmer) was used
according to the manufacturer's
instructions. The sequencing reactions
were run on an ABI 373 or 377
sequencer (Perkin Elmer).
5.10.2. SSCP analysis and non-
denaturing-PAGE analysis
In SSCP analysis the denatured PCR
amplified fragments were separated in
0.8xMDE™ gel (FMC) for 5-18 hours at
10 W and the alleles were visualised by
silver staining. In the non-denaturing-
PAGE analysis the PCR amplified
fragments were run on a 12%
polyacrylamide gel for 2-3 hours at 100
V, and the alleles were visualised with
ethidium bromide.
5.11. Gene expression studies
5.11.1. Northern blot analysis
Two µg of polyA RNA or 10 µg of total
RNA extracted from the EBV
transformed lymphoblasts of MUL
patients and non-MUL controls was run
on a 1.5% agarose gel electrophoresis
for 4-6 hours at 100 W. The RNA
fragments were transferred to nylon
membrane over night in 2xSSC.
Commercially available multiple tissue
northern blots were also analyzed
(Human and Human II, Clontech). RT-
PCR fragments and a β-actin control
probe (Clontech) were used as probes.
The probes were labelled with
[α32P]dCTP by random-priming using
the RediPrimeII Kit (Amersham
Pharmacia). After labelling the probe
was purified with a Nick column
(Amersham Pharmacia), and blocked
with both human placental DNA (0.25
µg/µl) and salmon sperm DNA (0.5
µg/µl). The filters were hybridised for 2
hours at 65 °C in ExpressHyb solution
(Clontech) and washed at 65 °C
according to the manufacturer's
instructions. After autoradiography for
2-6 hours at -80 °C X-ray films were
developed.
5.11.2. RT-PCR analysis
cDNA was synthesised from
lymphoblastoid RNA using M-MLV
Reverse Transcriptase (Promega) and
random hexamers (Promega). RT-PCR
reactions were performed under standard
PCR conditions and RT-PCR products
were run on 1% agarose gel and






Sequence editing and aligning was
performed using Sequencher 3.1 (Gene
Codes Corporation). The nucleotide
sequence databases and protein
predictions programmes used in the
analysis of KIAA0898 are shown in
Table 3.
Table 3. The nucleotide sequence databases and protein prediction programmes
used in the analysis of KIAA0898.
Nucleotide sequence databases www-address
BlastN and BlastP comparisons http://www.ncbi.nlm.nih.gov/BLAST/
The Unigene Resources http://www.ncbi.nlm.nih.gov/UniGene/index.html












6.1. Initial assignment of the MUL
locus by linkage analysis (I)
A genome-wide search for linkage with
240 polymorphic markers was carried
out in six multiplex families. After
comparing familywise the alleles of the
affecteds, the marker D17S787 at 17q
was found to give a result suggestive of
linkage: in five out of six families the
alleles of the affecteds were identical,
and in one family a recombination was
detected. Four markers from four
separate chromosomal regions showed
identical alleles in four families. At these
four loci, a recombination or an
uninformative meiosis was detected in
two families. More markers were
genotyped around all the five regions
and a linkage analysis was performed.
The four regions with identical alleles
were clearly excluded, whereas the 17q

























A schematic representation of the chromosomal
assignment of the 7 cM MUL region on 17q.
Additionally two well-known loci on 17q, BRCA1
and SOX9, are shown on the left hand side. The
genetic map of the initial 7 cM MUL region is





Seven families with only one affected
were included in the study. The critical
MUL region was defined by
recombinations to a 7 cM region
between markers D17S1799 and
D17S948 (Fig. 6). Within this region the
highest two-point lod score of 4.46 (at
θ=0.0) was obtained at locus D17S1604.
In the multipoint linkage analysis with
VITESSE a maximum LOD score of
5.01 was reached at loci D17S1606-
D17S1853 and at locus D17S1604. The
results strongly support the existence of
MUL locus on chromosome 17q and
provide strong evidence for genetic
homogeneity in MUL in Finland.
6.2. Refinement of the MUL locus by
linkage disequilibrium analysis (I and
II)
The alleles at marker loci on the MUL
chromosomes of 13 patients were
compared with alleles on the normal
chromosomes of the parents. A highly
significant (p<0.001) allelic association
was observed for the markers
D17S1606, D17S1853 and D17S1604,
the most common allele occurring in
74%, 85%, and 44% of the MUL
chromosomes, but in 15%, 11%, and 4%
of the normal chromosomes,
respectively.
Luria-Delbrück analysis was used to
estimate the genetic distances between
the MUL gene and the marker loci
demonstrating significant allelic
association. The pexcess values for
markers D17S1606, D17S1853 and
D17S1604 were 0.70, 0.83, and 0.42
respectively. The genetic distance
between MUL and three marker loci was
calculated by assuming a single
founding mutation, a MUL gene
frequency (q) of 0.005, and a mutation
rate (µ) of 5 x 10-6. By these criteria the
MUL gene resides closest to D17S1853.
Assuming 50 generations since
founding, the distance of MUL from
D17S1853 was estimated to be 0.25 cM
and assuming 25 generations, 0.65 cM.
These estimates correspond to a MUL
region of 500 kb and of 1300 kb,
respectively, assuming that 1 cM
corresponds to 1 Mb in the region.
The Luria-Delbrück analysis is
considered to work well for recessive
disorders that are primarily due to a
single disease-causing mutation (Jorde
1995), as in the case of diastrophic
dysplasia (Hästbacka et al. 1994). On the
other hand, in progressive myoclonus
epilepsy of Unverricht-Lundborg type
that is caused by a enriched mutation in
Finland, the analysis was slightly
misleading (Virtaneva et al. 1996,
Pennacchio et al. 1996). The Luria-
Delbrück estimates are influenced by the
relation of genetic and physical
distances, that are known to vary
substantially at different genomic
regions.
The critical MUL region (defined
below) has later been shown not to
follow the average rule of 1 cM
corresponding to 1 Mb. Instead, the 1
cM interval between markers
D17S1606/D17S1853 (at the same
genetic locus) and D17S1604 on the
genetic map corresponds most likely to
at least 2 Mb (see 6.5.). Furthermore, the
Luria-Delbrück estimates are known to
be subject to variation due to e.g.
sampling error (Hästbacka et al. 1992).
The analysis of the novel markers
isolated by us (see below) from the
region between D17S1853 and
D17S1604 revealed significant allelic
association. Using the DISLAMB
programme (Terwilliger 1995) the
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strongest associations between MUL and
an allele were detected at 95-CA, 272a-
CA, 272b-CA, 132-CA, and 58-CA (λ-
value > 0.95 with p-value < 10-5; see
also Figure 7).
6.3. Refinement of the MUL locus by
haplotype analysis (unpublished, II,
III)
The initial haplotype analysis in 26




Analysis of historical recombinations
in haplotypes constructed from the novel
markers (see below) in 42 MUL
chromosomes refined the critical MUL
region to a 1400 kb region between
markers D17S1290 and 52-CA (Table 4;
Fig. 7). Altogether five centromeric and
four telomeric historical recombinations
were detected in MUL chromosomes
(Table 4).
After analysing a total of 100
chromosomes, the MUL locus was
further refined by haplotype analysis to
an approximately 800 kb between
marker locus 95-CA and 58-CA (Table
4). Two patients were compound
heterozygotes for the ancestral haplotype
and a different haplotype which most
likely represents a "minor" MUL
mutation in the Finnish population
(Table 4).
The 800 kb critical MUL region is
relatively wide. In numerous other
positional cloning projects the haplotype
analysis has enabled to refine the critical
gene region to less than 200 kb
(Virtaneva et al. 1996, The Finnish-
German APECED Consortium 1997,
Kestilä et al. 1998). The relatively wide
shared haplotype in MUL can be caused
by a recent expansion of the ancestral
mutation or a small number of
chromosomes studied. Additionally,
gene-rich regions, such as the MUL
region, are sometimes less prone to
crossing-over events.
Table 4. The haplotype analysis of the Finnish MUL patients. In the first row the major Finnish haplotype
is defined. The haplotypes restricting the MUL gene region are shown below. The last row indicates the
Finnish minor haplotype found in two patients in a compound heterozygote form. n= not determined.
number of
disease
chromosomes cen D17S1290 95-CA 272a-CA 272b-CA 132-CA 58-CA 52-CA D17S1604 tel
n 7 4 4 7 3 1 6 4
4 7 4 4 7 3 1 2 2
2 5 4 4 7 3 1 6 4
3 5 4 4 7 3 1 6 6
1 5 6 4 7 3 1 6 n
1 7 4 4 7 3 4 3 n
1 7 4 4 7 3 5 3 n
2 6 3 5 4 4 5 6 15
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6.4. Meckel syndrome was assigned to
the same chromosomal region as MUL
(II)
Interestingly, the locus for Meckel
syndrome (MKS, MIM No. 249000) was
assigned to chromosome 17q21-24
(Paavola et al. 1995) in the same genetic
region as MUL. The phenotype of MKS
is different from that of MUL as the
disorder leads to death soon after birth.
MKS is characterised by central nervous
system malformations, polycystic
kidneys, cystic and fibrotic changes of
the liver, and polydactyly (Salonen
1984), none of which are seen in MUL.
MKS also belongs to the disorders of the
Finnish disease heritage (Salonen 1984).
Globally MKS seems to be
heterogeneous with a wide spectrum of
phenotypes and locus heterogeneity
(Roume et al. 1998).
The critical MKS region defined by
haplotype analysis overlaps for 600 kb
with the 800 kb MUL region (data not
shown). However, the conserved
haplotypes in the region were different
in MUL and MKS patients (data not
shown) excluding allelic homogeneity.
The haplotype analysis leaves the
possibility of different mutations in the
same gene in MKS and MUL still open.
There are several examples of genes
responsible for more than one disease
(reviewed by Romeo and McKusick
1994).
6.5. Construction of the physical map
on 17q22-23 (II and III)
Six novel dinucleotide repeat markers
were isolated from PAC (95i19, 52i20,
and 58p18) and BAC (272g3 and
132i10) clones of the region. A CHLC
marker, D17S1290, was assigned into
the genomic clones within this region.
In addition, the detailed physical map
enabled us to precisely localise four
genes SFRS1, MPO, BCL5, and
RAD51c; a total of 20 ESTs of both
known and unknown homology; and two
cDNA clones, KIAA0647 and
KIAA0898.
The position of the PAC and BAC
clones in relation to each other was also
confirmed by the fiber-FISH method.
Pulsed-field gel electrophoresis (PFGE)
was used to determine the insert sizes of
the PAC and BAC clones of the
minimum tiling pathway. According to
both the PFGE data and fiber-FISH, the
size of the contig was estimated to be
approximately 1400 kb (see Figure 7).
The MKS-MUL region was covered
with bacterial clones at least two times
and the overlaps were confirmed by both
STS-content mapping and fiber-FISH
analysis. Recently, a demand for at least
five-times coverage has emerged in
order to increase the reliability of the
contigs. Even though the MKS-MUL
contig does not meet this criteria, the
double checking of overlaps by PCR and
fiber-FISH and the high density of STS
markers should account for the
reliability of the contig.
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The physical map on 17q22-23.
Non-chimeric YAC clones mapping to the region are shown as open bars. The PACs are indicated
by black bars (214g11 is a P1 clone), and the BACs by gray bars. For the orientation of the clones
either sp6 or t7 end of the clones are marked. The polymorphic markers used for the genetic mapping
are shown in bold letters on the top, while the ESTs and genes are marked with gray text. Five
sequenced bacterial clones are also shown in the map; hRPK.506h21, hRPC.1171i10, and
hRPC.1096f1, hRPK.112_H_11, and hRPC.1081_P_3. The recently identified cDNA clones,
KIAA0898 and KIAA0647, are shown below as open bars and are at least partly mapping to
sequenced clones, hRPC.1081_P_3 and hRPK.112_H_11, respectively. The critical MUL region





6.6. Exclusion and evaluation of
candidate genes at 17q (I, II, III, and
unpublished)
During the positional cloning effort of
the MUL gene several positional
candidate genes emerged. In some of
these the putative role in MUL was not
evident, whereas some were considered
as good functional candidates. The
former group includes the serine-
arginine-rich splicing factor gene
(SFRS1), the myeloperoxidase gene
(MPO), and the B-cell leukemia/
lymphoma-5 gene (BCL5), and the latter
the growth hormone (GH) gene
complex, the HOXB gene cluster, the T-
box transcription factor gene (TBX2),
and the peanutlike-2 gene (PNUTL2).
SFRS1, MPO, and BCL5 were localised
to the MUL clone contig but resided
centromeric to 95-CA that defined the
centromeric border of the critical region
for MUL. Thus they were positionally
excluded. The functionally relevant
positional candidate genes were
evaluated and their exclusion is
described here in more detail.
Mutations involving different genes
of GH complex (George et al. 1981)
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have been observed in growth hormone
deficiency (Phillips & Cogan 1994).
Since one of the key findings in MUL is
short stature, and since some of the
MUL patients are growth hormone
deficient (Lipsanen-Nyman 1986,
Lapunzina et al. 1995, Lenko et al. 1982,
Haraldsson et al. 1993) the GH locus
assigned to 17q22-q24 (George et al.
1981) was considered a putative
candidate for MUL. A microsatellite
repeat polymorphism at the GH locus
(Polymeropoulos et al. 1991) showed a
recombination in family 13 excluding
the GH locus as the MUL gene.
Mammalian homeobox genes (HOX)
regulate the vertebrate embryogenesis
(McGinnis & Krumlauf 1992). As MUL
is a developmental disorder the HOXB
cluster located in 17q21-22 (Solomon &
Baker 1989) was considered a putative
candidate. A microsatellite repeat
marker (Deinard et al. 1992) at the
HOXB locus (Acampora et al. 1989) did
not reveal any recombinations in MUL
families, but HOXB was excluded as a
likely MUL candidate based on the
absence of linkage disequilibrium at the
marker.
The TBX2 gene is expressed in mouse
in many stages and tissues during the
embryonic development (Chapman et al.
1996). TBX2 was cloned and assigned to
17q23 (Campbell at al. 1995). The fiber-
FISH hybridisation of a clone positive
for TBX2 on free DNA fibers showed
that TBX2 is located at least 2 Mb
telomeric to the marker D17S1604. Thus
TBX2 could be positionally excluded as
the causative gene for MUL.
The PNUTL2 gene related to proteins
involved in cytokinesis and
development, was shown to map to the
MUL region (Paavola et al. 1999).
Therefore it was considered a good
positional-functional candidate. The
genomic sequencing in patients and
controls did not reveal mutations in the
exons or in the exon-intron boundaries
of PNUTL2 (unpublished data).
Furthermore, the Northern blot analysis
performed on lymphoblast mRNA from
patients did not reveal size differences of
the transcript or altered level of
expression when compared to that of
controls (unpublished data). According
to this data PNUTL2 was excluded as the
MUL gene.
Eventually, one gene, RAD51c
(Dosanjh et al. 1998), as well as two
cDNA clones KIAA0647 (Ishikawa et
al. 1998) and KIAA0898 (Nagase et al.
1998) resided in the MUL region. The
possible role of RAD51c in MUL is
difficult to evaluate as little is known of
the function of the gene. RAD51c is
possibly involved in recombinational
repair of DNA damage and meiotic
recombination.
KIAA0647 was identified from
human brain cDNA libraries and is
thought to be involved in signal
transduction although the wide
expression pattern suggests a more
general function. The closest protein
neighbours of KIAA0647 are
myotubularins, suggesting a likely
association of KIAA0647 with a
muscular disease.
KIAA0898, also identified from
human brain cDNA libraries, was
categorised as “functionally
unclassified” since only weak
homologies to known gene products
were identified. An analysis of the
amino acid sequence of KIAA0898
revealed that the protein belongs to a
group of zinc finger proteins, which are
known to often act as transcription
factors, rendering it to a putative
candidate gene for MUL. Later
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KIAA0898 was shown to be the MUL
gene using mutation analysis.
6.7. Analysis of the MUL gene (III)
6.7.1. Mutation analysis of MUL
KIAA0898 is a 4,111 bp cDNA that
includes an open reading frame (ORF) of
2892 bp thereby predicting a polypeptide
of 964 amino acids (aa) starting from the
first ATG codon with a Kozak consensus
sequence (at position 46 in GenBank
accession). The ORF of KIAA0898 was
analysed in four MUL patients
representing five different haplotypes by
sequencing overlapping RT-PCR
amplified fragments. Four frameshift
mutations were identified in the patients
indicating that KIAA0898 is the MUL
gene.
The major Finnish mutation (Finmajor)
is an A-to-G transition altering the
consensus dinuclotide sequence of the 3´
splice site (AG) at position c.493-2
(Table 5). The next AG dinucleotide
occurs after three base pairs and acts as
the splice acceptor site producing a 5-bp
deletion at c.493-497. The deletion leads
to a premature STOP at codon 175 and
thereby results in a predicted protein of
174 aa. The Finmajor cosegregates with
the Finnish ancestral MUL haplotype,
and is found in 98/100 of the Finnish
MUL chromosomes. The carrier
frequency of Finmajor varies regionally in
Finland. In the high-risk region (Savo
and North Carelia; Fig. 1), a relatively
high carrier frequency of 1:24 was
detected (Table 5). This is more than
expected by the disease incidence.
Possibly, the actual incidence of MUL in
the high-risk region is higher than
reported. The phenotype of MUL is
variable and complex creating
difficulties in the diagnosis. Especially,
the “milder” MUL patients without
cardiac involvement might be
undiagnosed. In the rest of the country
no carriers of the mutation were found in
99 individuals.
The second MUL mutation is a 1-bp
deletion of a G at nucleotide c.2212
leading to a premature STOP at codon
768 (Table 5). We identified this
mutation (Finminor) in one chromosome
in each of two Finnish patients that are
compound heterozygotes for the
ancestral MUL haplotype and a different
haplotype predicted to represent the
“minor” MUL mutation in the Finnish
population. No carriers of the Finnish
minor mutation were detected in 316
Finnish control individuals, which is in
agreement with the rare occurrence of
the mutation in MUL patients (Table 5).
In a Czech patient homozygous for a
“private” haplotype across the entire
MUL region (data not shown) we
identified on both chromosomes a 5-bp
deletion of ACTTT at nucleotides c.838-
842 (Table 5). No carriers of the Czech
mutation were found in 190 CEPH
control individuals. The fourth mutation
is a 1-bp insertion of an A after
nucleotide c.1346 (Table 5). The
mutation disrupts the reading frame
causing a premature STOP at codon 458.
This mutation occurs in a homozygous
form in an American patient suggesting
that the parents are distantly related even
though the disease chromosome
haplotypes were not identical (data not
shown). No carriers of the American




Table 5. The MUL mutations.
Mutation Predicted consequence Carrier frequency
c.493-2A>G, Finmajor frameshift, truncated 174 aa
protein
1:24 (9:217) in the high
risk MUL regions in
Finland
no carriers in 99 controls
elsewhere in Finland
c.2212delG, Finminor frameshift, truncated 767 aa
protein
no carriers in 316 Finnish
controls
c.838delACTTT, Czech frameshift, truncated 334 aa
protein
no carriers in 190 CEPH
controls
c.1346insA, American frameshift, truncated 457 aa
protein
no carriers in 200 CEPH
controls
6.7.2. Nucleic acid sequence analysis of
MUL
BLAST comparisons revealed no
significant homologies between MUL
and previously known genes at the
nucleotide level, whereas at the amino
acid level several significant homologies
appeared at approximately aa 1-230
including zinc-finger proteins and
RING-finger proteins.
Unigene Homo Sapiens database
included altogether 43 EST sequences
for MUL mostly from the 3´end of the
cDNA sequence. Two 5´ end ESTs were
utilised to identify a STOP codon at
position –157 before the first ATG. The
EST sequences do not cover the full
length cDNA of MUL.
Approximately one third of MUL
cDNA, a 1.1 kb stretch from the 3´ end
of the cDNA, maps to the clone
hRPC.1081_P_3 that has been
sequenced at the Whitehead
Institute/MIT Center for Genome
Research (Fig. 7). This 3´ end of MUL
consists of seven exons ranging from 83
to 309 bps on a genomic region of
approximately 36 kb.
We identified 15 homologous mouse
ESTs and seven rat ESTs that were 84-
93% and 84-90%, respectively, identical
to the human gene, suggesting the




6.7.3. Amino acid sequence analysis of
MUL
A detailed analysis of MUL revealed
that the protein belongs to a group of
RBCC proteins that include a RING
finger, one to two B-boxes, and a coiled-
coil domain. In MUL the RING finger is
located at aa 16-57, the B-box domain at
aa 88-134, and the coiled coil region at
aa 142-235 (Fig. 8).
In addition, MUL contains a NS
domain at aa 232-421 (Fig. 8). This
domain, which is also found in C.
elegans, was identified originally in the
N-terminus of the speckle-type POZ
protein (SPOP) and appears to be
required for localisation of the SPOP
protein to nuclear speckles.
Two aspartate-glutamate-serine-rich
sequences (DES) were identified
between aa 416-550 and 895-919 with
weak homologies to several




The MUL protein belongs to the RBCC protein family.
The RING finger is located at aa 16-57, the B-box domain at aa 88-134,
and the coiled-coil region at aa 142-235. Additionally a NS domain
at 232-421, and two aspartate-glutamate-serine rich sequences (DES)
were identified at aa 416-550 and 895-919.
DES
RING B-box coiled-coil
6.7.4. Protein predictions of MUL
The putative structure of the protein
encoded by MUL was analysed with
several computer programmes. The
molecular weight predicted from the 964
amino acids is 108 kD. The PSORT II
programme predicted the localisation of
the MUL protein to the nucleus (65.2%),
cytoplasm (26.1%), and cytoskeleton
(8.7%). Many of the RBCC proteins
have been localised to the nucleus or the
cytoplasm (Meroni et al. 1999).
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Several potential modification sites,
such as four N-glycosylation sites, 15
protein kinase C phosphorylation sites,
23 casein kinase II phosphorylation sites,
two tyrosine kinase phosphorylation
sites, 13 N-myristolation sites, a leucine-
zipper pattern, and a myc-type helix-
loop-helix (HLH) dimerization domain
signature were identified using the
Scanprosite programme.
Hydrophobicity predictions did not
reveal strong hydrophobic regions in the
MUL polypeptide suggesting that MUL
is not likely a transmembrane protein.
6.7.5. Expression analysis of MUL
The tissue expression pattern of MUL
was studied using a 507 bp RT-PCR
fragment from the coding region
(nucleotides 947-1452) to probe human
multiple tissue Northern blots (Fig. 9).
In all tissues studied an RNA
transcript of approximately 4.4 kb that
corresponds to the full length mRNA
was detected. Strong signals of
approximately 3.9 kb from testis and 2.6
kb from heart were also detected.
Furthermore, most tissues studied
showed two signals around 2 kb.
On the other hand, RT-PCR reactions
from human brain, heart,
lymphoblastoid, placental, and testis
RNA did not produce clear evidence of
multiple RNA fragments (data not
shown). These data suggest the presence
of highly homologous genes rather than
alternative splicing of MUL.
Fig. 9
Human multiple tissue northern blot analysis of MUL using a probe from the coding region. In all tissues
tested a signal of approximately 4.4 kb is detected. In addition, a strong hybridization signal of 3.9 kb in
testis and 2.6 kb in heart is seen. Most tissues also show two signals less than 2 kb in length. The lower
panel provides loading controls following hybridization with a β-actin probe.
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6.7.6. Evaluation of the consequences
of the MUL mutations
Truncating mutations, like the ones
detected in MUL, are described to have
two kinds of consequences. On one
hand, the mRNAs carrying premature
chain termination codons are frequently
degraded in vivo (Culbertson 1999).
Thus, a complete loss of function of
MUL is possible. On the other hand, a
truncated protein lacking some of the
normal C-terminal sequence is produced
at some occasions (Lehrman et al. 1987).
The effect will then depend on the
stability of the polypeptide product, the
extent of the truncation, and the
functional importance of the lacking
amino acids.
So far, functional data is available for
one mutant RBCC protein, midin. The
MID1 gene encodes midin and is
mutated in Opitz syndrome (OS)
(Quaderi et al 1997). Midin co-localizes
with microtubules, is able to form
homodimers mediated by the RBCC
motif, and forms large protein
complexes within the cell (Cainarca et
al. 1999). Both missense and truncating
mutations which, except for one, retain
the RBCC motif intact have been
described in the MID1 gene (Quaderi et
al. 1997, Cainarca et al. 1999).
Functional analysis of those midin forms
resulting from truncating mutations in
which the RBCC domain is intact,
suggests only partial loss of MID1
function as lowered levels of expression
and retained ability to form multiprotein
complexes and homodimers, but
impaired microtubule binding have been
identified (Cainarca et al. 1999). Thus,
in OS the disease phenotype does not
appear to arise directly from loss of
function related to the tripartite RBCC
motif. Interestingly, three out of four
mutations in MUL also leave the RBCC
motif intact. Whether a similar, partly
functional truncated protein is formed in
MUL remains to be studied.




In this study the gene for Mulibrey
Nanism (MUL) was identified by
positional cloning. Initially, the MUL
locus was assigned to chromosome 17q
by linkage analysis. Linkage
disequilibrium and haplotype analysis
were utilised in the subsequent
refinement of the MUL locus to a 800 kb
region. A cDNA clone, KIAA0898, was
found out to be a positional and a
putative functional candidate for MUL.
Mutation analysis of KIAA0898
revealed four independent MUL
associated mutations, thus providing
strong evidence for KIAA0898 being the
MUL gene.
In this positional cloning project the
power of “cloning in silico” is well
demonstrated. As the refined MUL
region remained relatively wide, it
would have been a major effort to
identify the existing genes of the region.
This was not necessary since several
expressed sequences were already
available for mutation analysis in the
databases as ESTs, cDNA clones and
genes.
Before this study the diagnosis of
MUL was established exclusively on the
basis of the complex and variable
phenotype. The identification of the
MUL gene facilitates the diagnostics of
Mulibrey Nanism as DNA-based testing
is now available. Furthermore, families
with MUL patients have the access to
prenatal diagnosis if they so wish.
Genetic counselling of MUL is also
improved.
The identification of the MUL gene is
the first step in unravelling the molecular
pathogenesis of MUL. The identification
of the MUL gene also provides a
possibility to develop animal models for
MUL, which may eventually lead to
more effective treatment including gene
therapy. Additionally, it is now possible
to study the function of mutated and
wild-type MUL proteins in cell. As
MUL is a developmental disorder the
study of the normal function of the MUL
protein will inevitably reveal important
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